Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC203 TIL in Pancreatic Ductal Adenocarcinoma
NCT06828328Phase 1Recruiting
- Sponsor
- Juncell Therapeutics
- Start
- Feb 2025
- Primary completion
- Jan 2028
- Modality
- Gene Editing, Gene Silencing, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC203 in pancreatic ductal adenocarcinoma (PDAC), sponsored by Juncell Therapeutics. Primary endpoint: Adverse Events at 6 months. Started Feb 2025; status: recruiting.
02
Drugs
GC203
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06828328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06828328.